Skip to main content
Top
Published in: European Journal of Pediatrics 2/2014

01-02-2014 | Original Article

Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis

Authors: Pauline De Bruyne, Ann De Guchtenaere, Charlotte Van Herzeele, Ann Raes, Jo Dehoorne, Piet Hoebeke, Erik Van Laecke, Johan Vande Walle

Published in: European Journal of Pediatrics | Issue 2/2014

Login to get access

Abstract

Desmopressin 120 μg oral lyophilisate and 200 μg tablet are considered bioequivalent, based on extrapolation of studies in a limited number of adults and on one dose-finding study of desmopressin oral lyophilisate in children. However, no comparative pharmacokinetic study in children was executed confirming this statement. No data are available on the influence of food intake on the bioavailability of desmopressin tablet in a pediatric setting, although studies in adults have documented that food intake results in a significantly lower desmopressin plasma concentration. In this study, we analyzed plasma concentrations of desmopressin oral lyophilisate and tablet with concomitant food intake. Twenty-three children with monosymptomatic nocturnal enuresis (mean age, 12.7 years) were recruited. Two tests were performed on two separate days in identical conditions with a standardized food and fluid intake. Desmopressin was administered as desmopressin tablet or desmopressin oral lyophilisate immediately after a meal. Desmopressin plasma concentration was measured at 1 h, 2 h, and 6 h postdosing. No significant difference in plasma concentration of 120 μg desmopressin oral lyophilisate and 200 μg tablet was demonstrated, even with concomitant food intake. A significant difference in variability was found, identifying a smaller variance for desmopressin oral lyophilisate plasma concentrations at all time points. This study demonstrates comparable plasma levels for desmopressin oral lyophilisate, despite the lower dose. The dosage for desmopressin oral lyophilisate is more predictable due to the significantly smaller variance. Therefore, desmopressin oral lyophilisate seems more suitable, especially in the younger age group for which time interval between dinner and drug administration is limited.
Literature
1.
go back to reference (EMA), E. M. A. (2000). Note for guidance on the investigation of bioavailability and bioequivalence (EMA), E. M. A. (2000). Note for guidance on the investigation of bioavailability and bioequivalence
3.
go back to reference Antosova Z, Mackova M, Kral V, Macek T (2009) Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 27(11):628–635PubMedCrossRef Antosova Z, Mackova M, Kral V, Macek T (2009) Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 27(11):628–635PubMedCrossRef
5.
go back to reference De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5–16PubMedCentralPubMedCrossRef De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5–16PubMedCentralPubMedCrossRef
6.
go back to reference De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, Walle JV (2011) Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol 185(6):2308–2313PubMedCrossRef De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, Walle JV (2011) Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol 185(6):2308–2313PubMedCrossRef
7.
go back to reference Dehoorne JL, Raes AM, van Laecke E, Hoebeke P, Vande Walle JG (2006) Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. J Urol 176(2):754–757, discussion 757–758PubMedCrossRef Dehoorne JL, Raes AM, van Laecke E, Hoebeke P, Vande Walle JG (2006) Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. J Urol 176(2):754–757, discussion 757–758PubMedCrossRef
8.
go back to reference Glazener CM, Evans JH (2002) Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 3, CD002112PubMed Glazener CM, Evans JH (2002) Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 3, CD002112PubMed
9.
go back to reference Hjalmas K, Arnold T, Bower W, Caione P, Chiozza LM, von Gontard A, Yeung CK (2004) Nocturnal enuresis: an international evidence based management strategy. J Urol 171(6 Pt 2):2545–2561PubMedCrossRef Hjalmas K, Arnold T, Bower W, Caione P, Chiozza LM, von Gontard A, Yeung CK (2004) Nocturnal enuresis: an international evidence based management strategy. J Urol 171(6 Pt 2):2545–2561PubMedCrossRef
10.
go back to reference Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157–1167PubMedCrossRef Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157–1167PubMedCrossRef
11.
go back to reference Neveus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, Djurhuus JC (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 176(1):314–324PubMedCrossRef Neveus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, Djurhuus JC (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 176(1):314–324PubMedCrossRef
12.
go back to reference Norgaard JP, Pedersen EB, Djurhuus JC (1985) Diurnal anti-diuretic-hormone levels in enuretics. J Urol 134(5):1029–1031PubMed Norgaard JP, Pedersen EB, Djurhuus JC (1985) Diurnal anti-diuretic-hormone levels in enuretics. J Urol 134(5):1029–1031PubMed
13.
go back to reference Osterberg O, Balchen T, Riis A, Senderovitz T (2006) Pharmacokinetics of desmopressin in children and adults using a new oral lyophilisate. Arch Dis Child 91:A31–A34 Osterberg O, Balchen T, Riis A, Senderovitz T (2006) Pharmacokinetics of desmopressin in children and adults using a new oral lyophilisate. Arch Dis Child 91:A31–A34
14.
go back to reference Osterberg O, Savic RM, Karlsson MO, Simonsson US, Norgaard JP, Walle JV, Agerso H (2006) Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol 46(10):1204–1211PubMedCrossRef Osterberg O, Savic RM, Karlsson MO, Simonsson US, Norgaard JP, Walle JV, Agerso H (2006) Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol 46(10):1204–1211PubMedCrossRef
15.
go back to reference Rittig S, Jensen AR, Jensen KT, Pederson EB (1998) Effect of fod intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (dDAVP) in hydrated normal subject. Clin Endocrinol (Oxf) 48:235–241CrossRef Rittig S, Jensen AR, Jensen KT, Pederson EB (1998) Effect of fod intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (dDAVP) in hydrated normal subject. Clin Endocrinol (Oxf) 48:235–241CrossRef
16.
go back to reference Schulman SL, Stokes A, Salzman PM (2001) The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis. J Urol 166(6):2427–2431PubMedCrossRef Schulman SL, Stokes A, Salzman PM (2001) The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis. J Urol 166(6):2427–2431PubMedCrossRef
17.
go back to reference Theunis M, Van Hoecke E, Paesbrugge S, Hoebeke P, Vande Walle J (2002) Self-image and performance in children with nocturnal enuresis. Eur Urol 41(6):660–667, discussion 667PubMedCrossRef Theunis M, Van Hoecke E, Paesbrugge S, Hoebeke P, Vande Walle J (2002) Self-image and performance in children with nocturnal enuresis. Eur Urol 41(6):660–667, discussion 667PubMedCrossRef
18.
go back to reference Van de Walle J, Van Herzeele C, Raes A (2010) Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf : Int J Med Toxicol Drug Exp 33(4):261–271CrossRef Van de Walle J, Van Herzeele C, Raes A (2010) Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf : Int J Med Toxicol Drug Exp 33(4):261–271CrossRef
19.
go back to reference van Kerrebroeck PN, Norgaard JP (2009) Desmopressin for the treatment of primary nocturnal enuresis. Pediatr Heal 3(4):317–327 van Kerrebroeck PN, Norgaard JP (2009) Desmopressin for the treatment of primary nocturnal enuresis. Pediatr Heal 3(4):317–327
20.
go back to reference Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V, Norgaard JP (2006) A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 97(3):603–609PubMedCrossRef Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V, Norgaard JP (2006) A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 97(3):603–609PubMedCrossRef
21.
go back to reference Vande Walle J, Stockner M, Raes A, Norgaard JP (2007) Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2(3):232–238PubMedCrossRef Vande Walle J, Stockner M, Raes A, Norgaard JP (2007) Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2(3):232–238PubMedCrossRef
Metadata
Title
Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis
Authors
Pauline De Bruyne
Ann De Guchtenaere
Charlotte Van Herzeele
Ann Raes
Jo Dehoorne
Piet Hoebeke
Erik Van Laecke
Johan Vande Walle
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 2/2014
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-013-2108-2

Other articles of this Issue 2/2014

European Journal of Pediatrics 2/2014 Go to the issue